<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693667</url>
  </required_header>
  <id_info>
    <org_study_id>PH-CP011</org_study_id>
    <secondary_id>93-EC-17-A-17-I1-0034</secondary_id>
    <nct_id>NCT00693667</nct_id>
  </id_info>
  <brief_title>Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women</brief_title>
  <acronym>PH3</acronym>
  <official_title>A Phase II, Double-Blind, Randomized, Placebo-controlled, Clinical Study of PH3 for the Prevention of Osteoporosis in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhytoHealth Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhytoHealth Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to evaluate the effectiveness and safety of
      PH3 for the prevention of osteoporosis.

      The secondary objectives are to identify the optimal dosage for subsequent studies and to
      provide basis for the next confirmatory study in study design, endpoints, and study
      methodologies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Markers</measure>
    <time_frame>four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Densitometry</measure>
    <time_frame>four weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 mg active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>750 mg active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH3</intervention_name>
    <description>Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women 40-60 years of age.

          2. Must be postmenopausal (0.5~5 years post cessation of menses) or ovariectomized or
             hysterectomy women who have documented elevated Follicle Stimulating Hormone FSH
             (&gt;30mIU/ml) with low serum estradiol (&lt;20 pg/ml).

          3. The lumbar vertebral BMD T-score is between -1and -2.5 SD.

          4. The body mass index (BMI) is between 19 and 29 kg/m2.

          5. Completed informed consent and signed informed consent form.

        Exclusion Criteria:

          1. Have diseases which may affect bone metabolism, e. g., hyper-or hypocalcemia,
             hyperthyroidism, osteogenesis imperfecta, malignancy, chronic gastrointestinal
             disease, extensive Paget's disease, alcoholism, and renal or hepatic impairment.

          2. Has taken drug therapy for osteoporosis within the previous six months (excluding
             calcium supplements) prior to this study.

          3. Chronic or continued use of hormone replacement drugs or medications that may affect
             bone calcium metabolism, for example, phosphate-binding antacids, many diuretics,
             adrenal or anabolic steroids, heparin, anticonvulsants, fluoride in excess of 1 mg/day
             and supplements of vitamin D or A in excess of RDAs.

          4. Vitamin D deficiency (1, 25-dihydroxyvitamin D is lower than the normal range of: 25.1
             pg/mL ~ 66.1 pg/mL).

          5. Patients with fracture history.

          6. Patients who can not promise to keep from taking stimulant drinks (for example,
             coffee, tea, alcoholic drink, and Coke) that may cause loss of bone calcium, during
             the study period.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsiang Tai Chao, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taipei Veteran General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>November 3, 2011</last_update_submitted>
  <last_update_submitted_qc>November 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>postmenopausal women</keyword>
  <keyword>botanical drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

